biomedicines

IMPACT FACTOR 3.9

Indexed in: PubMed

CITESCORE 5.2

an Open Access Journal by MDPI

Molecular Determinants of Neurodegenerative Diseases

Guest Editor:

Dr. Carlo Santambrogio
Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy

Deadline for manuscript submissions:
closed (30 June 2023)

Message from the Guest Editor

Dear colleagues,

Protein misfolding and the consequent aggregation and deposition of amyloid plaques are at the basis of severe and diffuse neurodegenerative dysfunctions. The pathways that lead a functional protein to a pathological state are characterized by a complex network of heterogeneous and transient species, making the investigation of these phenomena extremely challenging. This Special Issue is focused on scientific contributions highlighting the molecular factors that are critical in the onset or development of the disease (e.g., affecting the protein structure, modulating the aggregation kinetics and the aggregate morphology, inducing or abolishing toxicity, governing the prion-like spreading mechanism, etc.). Examples of such determinants are protein mutations, truncations or post-translational modifications, protein ligands, inhibitors of the aggregation pathway, molecules able to disassemble amyloid fibrils, etc. Original manuscripts, review articles, case reports, and commentaries related to this subject are all welcome.

- protein misfolding
- amyloid fibrils
- aggregation kinetics
- aggregate morphology
- aggregation inhibitor

biomedicines

IMPACT FACTOR 3.9 | Indexed in: PubMed | CITESCORE 5.2

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI